General Information of This Peptide-drug Conjugate (PDC)
PDC ID
PDC_02020
PDC Name
TATE-VCit-Ama
PDC Status
Investigative
Indication
In total 1 Indication(s)
Pancreatic cancer
Structure
Peptide Name
3-Tyr-Octreotate
 Peptide Info 
Receptor Name
Somatostatin receptor type 1 (SSTR1)
 Receptor Info 
Drug Name
Amatoxins
 Drug Info 
Linker Name
Val-Cit
 Linker Info 
Peptide Modified Type
Amino acid modifications; Cyclization modification
Modified Segment
D-amino acids
Ternimal Modification
N-terminal modification
Formula
C114H150N28O32S3
#Ro5 Violations (Lipinski): 5 Molecular Weight 2520.819
Lipid-water partition coefficient (xlogp) -5.5252
Hydrogen Bond Donor Count (hbonddonor) 31
Hydrogen Bond Acceptor Count (hbondacc) 38
Rotatable Bond Count (rotbonds) 43
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Pancreatic cancer
Efficacy Data Half maximal effective concentration (EC50)
2.3 ±0.8 nM
Administration Time 72 h
Evaluation Method MTS assay
MOA of PDC
Towards these ends, we report on the design of a modular and user-friendly approach to enable bio-orthogonal conjugation of synthetic amanitins to three different linkers that are elaborated to three potent peptide-amanitin conjugates that differ by their mode of toxin release, as defined by the linker. Octreotate (TATE-N3, 2) was chosen as it is a circulation-stable octapeptide somatostatin analog that agonizes somatostatin receptors (Kd &tide; 0.4 nM for sstr2). Targeting sstr2 has been successfully exploited for drug delivery, cancer imaging, and radiotherapy owing to the high levels of sstr2 expression on neuroendocrine tumors (e.g. carcinoids, pancreatic islet cell tumors, thyroid carcinomas, and small lung cancer to name a few). While this is the first report of an octreotate-amanitin conjugate, herein, octreotate serves as an exemplar to highlight the potential for developing peptide-amanitin conjugates in targeted applications.

   Click to Show/Hide
Description
With bioconjugates 5-7 in hand, we evaluated their cytotoxicity by assaying cell viability on an sstr2-positive rat pancreatic cancer Ar42J cells, using free amatoxins as controls. The MTS cell viability assay showed that all three PDCs were effective at reducing the viability of Ar42J cells in the low nM range, providing calculated EC50 values of 4.2, and 2.3 nM for conjugates 6 and 7, respectively; these displayed up to 1000-fold enhancement in apparent cytotoxicity compared to free amatoxins 3 and 4, both of which gave calculated EC50 values of &tide;2 μM. This points to successful targeting and intracellular accumulation of toxin inside cells through an sstr2-mediated uptake inside the cells. Further evidence supporting target-mediated uptake is the micromolar toxicity of bioconjugates to the sstr2-negative CHO cell line that is otherwise sensitive to non-targeted amanitin. In comparison to -amanitin and synthetic amatoxins 3 and 4, bioconjugates 5-7 are 7- to 14-fold less toxic to CHO cells (control cell line), likely owing to impaired uptake of octreotate-amanitin conjugates that must enter via diffusion mediated processes or other non-specific import mechanisms that are currently unknown. In addition, a blocking study was run in the presence of free TATE-N32, which led to the expected reduction in apparent toxicity.

   Click to Show/Hide
In Vitro Model Digestive system neoplasms AR42J (SSTR2+) cell CVCL_0143
Experiment 2 Reporting the Activity Data of This PDC [1]
Indication Pancreatic cancer
Efficacy Data Half maximal inhibitory concentration (IC50)
8.7 ± 0.5 μM
Administration Time 72 h
Evaluation Method MTS assay
MOA of PDC
Towards these ends, we report on the design of a modular and user-friendly approach to enable bio-orthogonal conjugation of synthetic amanitins to three different linkers that are elaborated to three potent peptide-amanitin conjugates that differ by their mode of toxin release, as defined by the linker. Octreotate (TATE-N3, 2) was chosen as it is a circulation-stable octapeptide somatostatin analog that agonizes somatostatin receptors (Kd &tide; 0.4 nM for sstr2). Targeting sstr2 has been successfully exploited for drug delivery, cancer imaging, and radiotherapy owing to the high levels of sstr2 expression on neuroendocrine tumors (e.g. carcinoids, pancreatic islet cell tumors, thyroid carcinomas, and small lung cancer to name a few). While this is the first report of an octreotate-amanitin conjugate, herein, octreotate serves as an exemplar to highlight the potential for developing peptide-amanitin conjugates in targeted applications.

   Click to Show/Hide
Description
With bioconjugates 5-7 in hand, we evaluated their cytotoxicity by assaying cell viability on an sstr2-positive rat pancreatic cancer Ar42J cells, using free amatoxins as controls. The MTS cell viability assay showed that all three PDCs were effective at reducing the viability of Ar42J cells in the low nM range, providing calculated EC50 values of 4.2, and 2.3 nM for conjugates 6 and 7, respectively; these displayed up to 1000-fold enhancement in apparent cytotoxicity compared to free amatoxins 3 and 4, both of which gave calculated EC50 values of &tide;2 μM. This points to successful targeting and intracellular accumulation of toxin inside cells through an sstr2-mediated uptake inside the cells. Further evidence supporting target-mediated uptake is the micromolar toxicity of bioconjugates to the sstr2-negative CHO cell line that is otherwise sensitive to non-targeted amanitin. In comparison to -amanitin and synthetic amatoxins 3 and 4, bioconjugates 5-7 are 7- to 14-fold less toxic to CHO cells (control cell line), likely owing to impaired uptake of octreotate-amanitin conjugates that must enter via diffusion mediated processes or other non-specific import mechanisms that are currently unknown. In addition, a blocking study was run in the presence of free TATE-N32, which led to the expected reduction in apparent toxicity.

   Click to Show/Hide
In Vitro Model Digestive system neoplasms AR42J (SSTR2+) cell CVCL_0143
References
Ref 1 Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells. RSC Chem Biol. 2021 Oct 7;3(1):69-78. doi: 10.1039/d1cb00036e. eCollection 2022 Jan 5.